Diabetes drug Byetta tied to kidney problems, says FDA

People with type 2 diabetes who are taking the blood-sugar-lowering drug Byetta may be at increased risk for kidney problems, including kidney failure, the U.S. Food and Drug Administration reported this week.

Submitted by Amy Tenderich

• 73 Views
• 2 Comments

UPDATE: Roche's New Diabetes Drug Works Better Than Byetta

Here's an article about taspoglutide and you don't have to subscribe to the WSJ to read it: ZURICH -(Dow Jones)- Roche Holding AG said Thursday its experimental diabetes drug taspoglutide worked better than a rival drug sold by Eli Lilly & Co. in lowering blood sugar, according to the results of a late stage study. October 29, 2009: 08:19 AM ET

Submitted by jayabee52

• 12 Views
• 0 Comments

Roche's New Diabetes Drug Works Better Than Byetta

Roche's experimental diabetes drug taspoglutide worked better than a rival drug sold by Eli Lilly & Co. in lowering blood sugar, according to the results of a late stage study.

Submitted by Amy Tenderich

• 73 Views
• 2 Comments

Once-weekly Amylin drug tops Januvia, Actos-study

A new once-weekly form of injectable diabetes drug Byetta (still awaiting FDA approval) proved superior to the widely used medicines Actos and Januvia in a clinical trial, according to data presented on Saturday.

Submitted by Amy Tenderich

• 137 Views
• 0 Comments

Amylin seeks FDA OK on once-weekly diabetes drug

This is the drug I wrote about here recently. It's an extended version of the twice-daily injectable drug Byetta, a version of a protein found in Gila monster saliva, and is being viewed by Wall Street as a way for Amylin to reinvigorate sales.

Submitted by Amy Tenderich

• 93 Views
• 1 Comment

Popular diabetes treatment could trigger pancreatitis, pancreatic cancer

In a study published in the online edition of the journal Diabetes, researchers from UCLA found that sitagliptin, sold in pill form as JANUVIA, caused abnormalities in the pancreas that are recognized as risk factors for pancreatitis and, with time, pancreatic cancer in humans.

Submitted by Amy Tenderich

• 181 Views
• 3 Comments

Amylin And Lilly Hope A New Byetta Study Eases Concern Over Drug-Safety Issues

Now, a March 13, 2009 Dow Jones news report, "Study Downplays Risk Of Amylin's Byetta, But Concerns Remain", brings us the latest developments concerning the issue of whether Byetta increases the risk of pancreatitis. According to this report, the professional journal Current Medical Research and Opinion, recently published the findings of an analysis that used an insurance company database to show that neither Byetta nor Januvia -- a diabetes drug from Merck & Co. --... read more

Submitted by DawnRJackson

• 88 Views
• 1 Comment

A Once-Weekly Diabetes Treatment that Aids with Weight Loss?

Amylin Pharmaceuticals is working on something they’re hailing as a potential miracle drug: the first-ever once-weekly diabetes treatment that’s guaranteed to bring down your blood sugar levels and help you lose weight and keep it off. It certainly sounds amazing, no?

Submitted by John Crowley

• 6257 Views
• 67 Comments

Pancreatic Disease Risk Increased by Type 2 Diabetes Drug Byetta

Byetta, a drug commonly prescribed for the treatment of type 2 (adult onset) diabetes, has been linked to an increased risk of deadly pancreatic disease. Dozens of Byetta patients have suffered a painful injury called hemorrhagic pancreatitis, or inflammation of the pancreas, that resulted in death or serious injuries. The Food and Drug Administration has issued several public advisories about Byetta’s connection to pancreatic disease and warned users about the risk.

FDA Issues Warnings... read more

Submitted by Avera

• 390 Views
• 0 Comments

FDA Byetta review likely to extend into 2009

Drug developers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday federal regulators likely will extend their review of the diabetes treatment Byetta as a possible stand-alone therapy into next year.

The Food and Drug Administration has not requested additional studies, San Diego-based Amylin said in a statement from both companies
Byetta currently is approved for use in combination with other diabetes medications to help people with type 2 diabetes control their blood... read more

Submitted by Avera

• 468 Views
• 1 Comment